N eprilysin (NEP) is a cell surface peptidase expressed in vascular cells, cardiac myocytes, lung, brain, renal epithelial cells, and fi broblasts.
3[H] Thymidine Incorporation
The effect of growth factors and neuropeptides on DNA synthesis was evaluated as reported previously. 8 
Western Blotting
Cell lysates were prepared and proteins separated on SDS-PAGE and transferred to nitrocellulose. Membranes were incubated with primary antibody and protein bands visualized by chemiluminescence. 8 GAPDH was used as a loading control. A Bio-Rad gel scanner and densitometer (Gel DocXR with Quantity 1 program) were used to assess the intensity of the bands obtained by Western blots.
Flow Cytometry
PASMCs were fi xed with paraformaldehyde 2% and methanol and stained with antibodies to PDGF receptor (PDGFR) α and β . Cells were analyzed using a Gallios fl ow cytometer (Beckman Coulter) and Summit 4.3 software (Beckman Coulter). Ten-thousand events were obtained and analyzed for the percentage of gated singlets and mean intensity. Overlay plots were obtained using Kaluza software. Four different paired cell isolates were used for analysis.
Lentivirus Infection
PASMCs were transfected with lentivirus expressing human fulllength NEP or peptidase dead mutant NEP (NEPX) at a multiplicity of infection of 10, as described previously. 8 
Small Interfering RNA Transfection
PASMCs were transfected with mouse specifi c small interfering RNA (siRNA; 10 nmol/L) or universal siRNA from Sigma Aldrich using Dharmafect Reagent from Dharmacon (Denver, CO) as per manufacturer recommendations. siRNA for NEP, PDGFR α , PDGFR β , and Src were obtained from Sigma. Cells were used 48 hours after transfection for migration and proliferation assays.
Endothelin A Receptor Antagonist Treatment
PASMCs were treated with endothelin A receptor (ET A R) antagonist ambrisentan (10 µ mol/L). NEP +/+ and NEP − / − mice on an FVB/n background were treated with the ET A R antagonist atrasentan (10 mg/kg) for 7 days in drinking water.
Statistical Analysis
Data were analyzed using GraphPad Prism 4.02 for Windows (GraphPad Software for Science Inc, San Diego, CA). Results are presented as mean ± SEM. The signifi cance of differences between 2 measurements was determined by unpaired, 2-tailed t tests; 1-way ANOVA was used for multiple comparisons followed by Fisher least signifi cance analyses. P < 0.05 was considered statistically signifi cant. The n for each experiment represents the number of cell isolates each obtained from a different mouse.
Results

Loss of NEP Leads to Increased Migration and Proliferation of Mouse PASMCs
Migration and proliferation of PASMCs are important mechanisms contributing to pulmonary vascular remodeling. 8 , 13 PASMCs from NEP − / − mice exhibited increased migration in the presence of serum (0.2%) and PDGF-BB (10 ng/mL) compared with wild-type cells assessed by wound healing and Boyden chamber assays ( Figure 1A -1C ). Proliferation was measured by 3 H-thymidine incorporation at 3 different doses of serum and PDGF and showed 3-to 4-fold higher incorporation in NEP − / − PASMCs compared with NEP +/+ cells ( Figure  1D and 1E).
Twelve of 15 different matched pairs of NEP +/+ and − / − PASMCs showed a major difference in proliferation on initial screening; these cell lines were used for further study. Enhanced smooth muscle cell outgrowth was also observed from NEP − / − pulmonary artery tissue cultured ex vivo compared with +/+ control (data not shown), suggesting that the differences observed in the phenotype were intrinsic to the pulmonary artery smooth muscle cell and not acquired over time in culture. Scratch assays performed in the presence of mitomycin (10 µ mol/L) had no effect on the enhanced migration of NEP − / − PASMCs, suggesting that proliferation did not contribute ( Figure S1A in the online-only Data Supplement).
Altering NEP Level Modifi es Migration and Proliferation of PASMCs
NEP
− / − PASMCs were infected with lentiviral vector expressing full-length human NEP. Migration and proliferation were measured after 48 hours. As seen in Figure 2A and 2B , replacing NEP in null cells attenuated migration and proliferation in the presence of serum (0.2%) and PDGF. The inset in Figure  2A shows levels of NEP expressed.
Inactivation of NEP in +/+ cells with a lentivirus expressing a peptidase dead mutant of human NEP (NEPX), with the inhibitor phosphoramidon, or knockdown of expression with siRNA to mouse NEP caused increased migration and proliferation in response to serum and PDGF similar to that observed with NEP − / − cells ( Figure 2C -2F ). There was a 4-fold increase in NEPX levels, as shown in Figure 2C . There was a 98 ± 2% decrease in NEP expression after treatment with siRNA, as shown in Figure 2E . Inhibition of NEP with phosphoramidon enhanced migration and proliferation in NEP +/+ PASMCs similar to that observed with mutant NEPX ( Figure S1B and S1C). NEPX had no effect on migration and proliferation in NEP − / − cells (data not shown), suggesting that the peptidase activity of NEP is required to inhibit the exaggerated responses in null cells and that substrates on NEP are mediating the effect. from 3 different populations was used for statistical analysis.
3[H] Thymidine Incorporation
The effect of growth factors and neuropeptides on DNA synthesis was evaluated as reported previously. 
Western Blotting
PASMCs showed a major difference in proliferation on initial screening; these cell lines were used for further study. Enhanced smooth muscle cell outgrowth was also observed from NEP − / − pulmonary artery tissue cultured ex vivo compared with +/+ control (data not shown), suggesting that the differences observed in the phenotype were intrinsic to the pulmonary artery smooth muscle cell and not acquired over time in culture. Scratch assays performed in the presence of mitomycin (10 µ mol/L) had no effect on the enhanced migration of NEP − / − PASMCs, suggesting that proliferation did not contribute ( Figure S1A in the online-only Data Supplement).
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Loss of NEP Increases PDGFR Expression and Signaling in PASMCs
To determine whether the enhanced migratory and proliferative responses to PDGF were due to an increase in receptor expression, we measured PDGFR α , β , and β Y751 levels by fl ow cytometry ( Figure 3A ) and Western blot ( Figure 3B and Figure  S2A ). Protein levels of PDGFR α , β , and activated β Y751 were signifi cantly higher in NEP − / − cells (Table S1 ). A decrease in mRNA for both receptors PDGFR α (0.67-fold) and β (0.56-fold) was observed in NEP null PASMCs, perhaps representing an autoregulatory mechanism to downregulate receptor expression ( Figure S2B ).
Src and PTEN infl uence PDGFR signaling by phosphorylation-dependent mechanisms and are also regulated by NEP. 14 , 15 As shown in Figure 3B , levels of Src Y416 and PTEN S380 were higher in NEP − / − PASMCs. Total PTEN levels trended lower (0.6-fold) in NEP − / − compared with +/+ cells but were variable and did not reach statistical signifi cance.
siRNA-mediated knock down of NEP in wild-type PASMCs caused a 1.8-fold increase in phosphorylated (p) PDGFR Y751 , a 1.5-fold increase in p-Src, and a 1.2-fold increase in p-PTEN similar to that seen in null cells ( Figure  3C ). Conversely, lentiviral expression of NEP in − / − PASMCs attenuated PDGFR, Src, and PTEN phosphorylation ( Figure  3D and 3E) .
We compared the effect of PDGF treatment on phosphorylation of PDGFR, Src, and PTEN in NEP +/+ and NEP − / − PASMCs, as shown in Figure 3F and 3G. PDGFR phosphorylation in NEP +/+ cells was transient and increased at 15 and 30 minutes, whereas a more sustained rise is seen in NEP − / − PASMCs. Total levels of PDGFR were not affected by the treatment. Figure 3H shows that the level of p-Src was 2-fold higher and total PTEN lower at 24 hours in NEP − / − PASMCs.
Inhibition of PDGFR Attenuates Migration and Proliferation in PASMCs
PASMCs treated with siRNA to PDGFR α , β , and α β were used to assess the contribution of the 2 receptors to migration and proliferation. As shown in Figure 4A , partial knockdown of each of the receptors was observed at 48 hours. Average expression levels from 3 different isolates were 55 ± 15% for PDGFR α , 45 ± 15% for β , and 25 ± 20% for α β siRNA. We cannot rule out some degree of antibody cross-reactivity to the 2 receptors contributing to the observed magnitude of each knockout. We found that selective PDGFR β , but not α , activation stimulated migration and proliferation in both cell types ( Figure 4B and 4C and Figure S3A and S3B). Results obtained from siRNA-mediated knockdown of PDGFR α , β , and α β show that PDGFR β was the predominant receptor contributing to migration and proliferation of PASMCs ( Figure 4B and 4C ). Cells treated with siRNA to PDGFR α maintained their migratory and proliferative response to PDGF-BB ( Figure 4B and 4C) .
We assessed levels of phospho-and total Src and PTEN in PASMCs treated with siRNA to PDGFR α , β , and α β . As seen in Figure 4D , knockdown of both PDGFR α and β caused a signifi cant decrease in p-Src, with total levels remaining unchanged. In the case of PTEN, knockdown of PDGFR increased both p-PTEN and total PTEN levels. Total PTEN levels were 1.8-fold higher in cells treated with PDGFR α β siRNA ( Figure 4E ).
We found that knockdown of PDGFR α β had signifi cant effects on Src kinase activation in PASMCs, suggesting that both receptors contribute to its activation ( Figure 4D and 4E). We think that the residual p-Src is attributed to PDGFRindependent and neuropeptide-dependent activation, because PDGFR β or α β siRNA completely inhibited basal p-Src 
Loss of NEP Increases PDGFR Expression and Signaling in PASMCs
To determine whether the enhanced migratory and proliferative responses to PDGF were due to an increase in receptor expression, we measured PDGFR α , β , and β Y751 levels by fl ow Figure 3A ) and Western blot ( Figure 3B and Figure  S2A ). Protein levels of PDGFR α , β , and activated β Y751 were signifi cantly higher in NEP − / − cells (Table S1 ). A decrease in mRNA for both receptors PDGFR α (0.67-fold) and β (0.56-fold) was observed in NEP null PASMCs, perhaps representing an autoregulatory mechanism to downregulate receptor
Inhibition of PDGFR Attenuates Migration and Proliferation in PASMCs
PASMCs treated with siRNA to PDGFR α , β used to assess the contribution of the 2 receptors to migration and proliferation. As shown in Figure 4A , partial knockdown of each of the receptors was observed at 48 hours. Average expression levels from 3 different isolates were 55 ± 15% for PDGFR α , 45 ± 15% for β , and 25 ± 20% for α cannot rule out some degree of antibody cross-reactivity to the 2 receptors contributing to the observed magnitude of each knockout. phosphorylation in NEP +/+ cells (data not shown). It is interesting that PDGFR α -associated Src activity does not infl uence migratory and proliferative responses, whereas PDGFR β does, suggesting that the 2 receptors couple to different downstream effectors.
Pharmacological inhibition of the PDGFR kinase (PDGFR inhibitor III) attenuated migration and proliferation of NEP 
Inhibition of Src Kinase Attenuates Migration and Proliferation in Mouse PASMCs
To determine the role of activated Src, we used siRNA to knock down Src and PP2, a Src kinase inhibitor, and measured effects on migration and proliferation. Western analysis confi rmed a 90 ± 10% decrease of Src protein with no signifi cant changes in Fyn and Lyn (data not shown). As seen in Figure  5A and 5B , treatment of PASMCs with Src siRNA inhibited migration and decreased proliferation to baseline levels in NEP − / − cells. Similarly, PASMCs treated with the inhibitor, PP2 (10 µ mol/L), had decreased migration and proliferation ( Figure S4A and S4B) . Knockdown of Src with siRNA reduced PDGFR Y751 phosphorylation to baseline levels and increased PTEN phosphorylation ( Figure 5C and 5D). Src siRNA also increased total PTEN levels. In comparison, inhibition of Src kinase with PP2 treatment abolished PDGFR Y751 phosphorylation but did not have signifi cant effects on p-PTEN ( Figure  S4C and S4D).
NEP Substrates Enhance PDGFR-Induced Migration and Proliferation in NEP +/+ Cells
Endothelin (ET)-1 and fi broblast growth factor 2 (FGF2) are representative substrates of NEP and have been demonstrated to play a role in the pathogenesis of pulmonary hypertension. 16 Levels and stability of ET-1 in cell culture supernatants and FGF2 in cell lysates were measured at baseline and were found to be higher in NEP − / − PASMCs ( Figure S5 ). NEP +/+ PASMCs were treated with PDGF in the presence or absence of ET-1 or FGF2. ET-1 enhanced PDGF-induced migration signifi cantly, which was attenuated by ambrisentan, an ET receptor antagonist ( Figure 6A and 6B ). FGF2 had more of a potentiating effect on the proliferative response of PDGF, which was attenuated by neutralizing antibody to FGF2 ( Figure 6C and 6D) . Inhibition of Src kinase with PP2 
Discussion
In this study we show that loss of the endopeptidase activity of NEP in PASMCs leads to increased migration and proliferation to growth stimuli. A peptidase-inactive mutant of NEP or knockdown with siRNA showed similar effects in wild-type cells, suggesting a role for NEP substrates, which include vasoconstrictors and dilators belonging to the G protein-coupled receptor family of ligands.
Our results demonstrate a mechanism by which NEP contributes to pulmonary vascular remodeling involving neuropeptide-mediated transactivation of growth factor receptor and signaling intermediates. 17 In NEP − / − cells, increased local concentrations of NEP substrates cause phosphorylation of Src kinase, inactivation of PTEN, and constitutive activation of PDGFR, which is partially reversed by the ET A R antagonist ambrisentan (Figure 8 ). Enhanced PDGFR signaling was observed in NEP − / − lungs and was attenuated by a ET A R antagonist.
Representative NEP substrates, ET-1 and FGF2, synergize with PDGF in wild-type PASMCs and increase phosphorylation of Src kinase and PDGFR. This phosphorylation is inhibited by ambrisentan and neutralizing antibody to FGF2 (Figure 7) . This study provides new insights into how ET receptor antagonists may exert some of their attenuating effects on vascular cell migration and growth (Figure 7 ).
PDGF and PDGFR are overexpressed in rodent models of pulmonary hypertension and in pulmonary arteries of patients with idiopathic pulmonary hypertension. 18 , 19 In experimental models it has been shown that PDGFR signaling is suppressed by BMPR2 (bone morphogenetic protein receptor 2), peroxisome proliferator-activated receptor-γ , and PTEN, and expression of these proteins is frequently lost in pulmonary hypertension. 20 -22 Our results suggest a novel mechanism by which a peptidase suppresses PDGF signaling and maintains smooth muscle cells in a quiescent state. Loss of NEP in PASMCs leads to activation of Src, resulting in phosphorylation and expression of PDGFR (Figures 3 and 4) .
A potential role for Src kinase has been described in the BMPR2 kinase-defi cient model of pulmonary hypertension. 23 In NEP null PASMCs, increased levels of NEP substrates, ET-1 and FGF2, caused Src activation and enhanced PDGFR signaling. 24 Inhibition or knockdown of Src decreases phosphorylation of PDGFR Y751 and attenuates migration and proliferation ( Figure 5C -5E) .
PTEN plays an important role in vascular biology, and its loss in mice causes pulmonary hypertension. 25 We have found that PTEN is inactivated by phosphorylation and expressed at lower levels in NEP − / − PASMCs compared with wild-type cells. Expression of NEP in null cells attenuated the increased phosphorylation of PTEN ( Figure 3D ). In addition, siRNAmediated knockdown of PDGFR or Src increases PTEN levels, whereas the kinase inhibitors decrease phosphorylation, suggesting an indirect regulatory mechanism ( Figures 4E, 4F , 5C, and 5D and Figures S4 and S5) .
Vasopeptidase inhibitors that target NEP have been shown to be benefi cial in systemic hypertension but were associated Figure 8C ). Ambrisentan decreased PDGFR and PTEN phosphorylation both at baseline and in response to PDGF ( Figure 8D and 8E). Src activity was inhibited only in response to PDGF. Analysis of lung lysates from NEP − / − versus NEP +/+ mice showed that p-PDGFR, p-Src, and p-PTEN were higher in the null tissue, suggesting that the pathway is activated in vivo. Treatment R antagonist atrasentan attenuated the baseline phosphosphorylation of Src kinase and PDGFR. This phosphorylation is inhibited by ambrisentan and neutralizing antibody to FGF2 ( Figure 7 ). This study provides new insights into how ET receptor antagonists may exert some of their attenuating effects on vascular cell migration and growth ( Figure 7 ). PDGF and PDGFR are overexpressed in rodent models of pulmonary hypertension and in pulmonary arteries of patients with idiopathic pulmonary hypertension. 18 , 19 In experimental models it has been shown that PDGFR signaling is suppressed by BMPR2 (bone morphogenetic protein receptor 2), peroxisome proliferator-activated receptor-γ , and PTEN, and expression of these proteins is frequently lost in pulmonary hypertension. 20 -22 Our results suggest a novel mechanism by 8 Hypertension
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with increased risk of angioedema. 26 , 27 Our results suggest that NEP inhibition in the pulmonary circulation could predispose the lung vasculature to injury. The role of NEP in different tissues may depend on local substrates available and resident cell composition and phenotype. These factors may vary in different vascular beds, emphasizing the need for understanding the mechanism of NEP action in the lung.
We demonstrate here for the fi rst time that NEP activity is required to maintain a quiescent pulmonary artery smooth muscle cell phenotype. This is consistent with our recent observations that NEP null mice have enhanced hypoxiainduced pulmonary vascular remodeling, and expression of NEP is decreased in lungs of patients with chronic pulmonary obstructive disease and pulmonary vascular remodeling. 8 , 28 We also show that ET-A antagonist effects may be mediated at least in part by inhibition of PDGFR responses. Strategies to increase NEP activity and expression or to directly inhibit Src and PDGFR in the lung may be of therapeutic benefi t for the prevention and treatment of pulmonary hypertension.
Perspectives
NEP is a cell surface enzyme that cleaves and inactivates both vasodilator and vasoconstrictor neuropeptides that are important for vascular function. Loss of NEP in PASMCs activates an integrated signaling network involving neuropeptides and growth factors, with Src kinase playing a central role. This cascade leads to increased migration and growth of PASMCs, an important component of vascular remodeling in pulmonary hypertension. Although NEP inhibitors may have protective effects in the systemic circulation, our observations also suggest that these drugs could predispose the lung vasculature to injury. Future studies will determine whether vascular bed-specifi c functions of NEP are attributed to intrinsic differences in cell types or to differences in substrates of NEP.
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